Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
BRIEFS
December 08, 2022
Drug-resistant infections kill an estimated 33,000 EU citizens every year. Without sufficient investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI from ince...
BRIEFS
December 08, 2022
Drug-resistant infections kill an estimated 5,400 Canadian citizens every year. Without sufficient R&D investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI ...
POLICY PAPERS
November 28, 2022
The experience of the COVID-19 pandemic—in the US and around the world—highlights the potential feasibility and importance of biomedical R&D for global health and welfare. Drawing from this experience and momentum, this paper argues that the US should deepen its engagement and ambition in global hea...
POLICY PAPERS
November 15, 2022
Antimicrobial drugs form the backbone of modern medicine. Yet over time, use of these drugs selects for mutations that survive exposure to those same drugs, driving “antimicrobial resistance,” or AMR. In the absence of sufficient R&D investment for new antimicrobials, deaths from drug-resistant infe...
POLICY PAPERS
November 10, 2022
Laboratories are fundamental components of health systems, but investments in strengthening laboratory systems are often inconsistent and inadequate in African countries. This paper qualitatively establishes the complex costs and benefits of strengthening laboratory capacity and systems within and a...
POLICY PAPERS
October 24, 2022
Cost information is essential for priority setting and optimized resource allocation in the healthcare sector, especially in low- and middle-income countries where resource constraints and opportunity costs are significant. Time-driven activity-based costing (TDABC) has gained prominence as a means ...
POLICY PAPERS
October 04, 2022
In this paper, we report the results of a horizon-scanning exercise to source opportunities for global health R&D investment—that is, high-value potential biomedical innovations which are currently underfunded but which could be transformative for health, quality of life, and health security in LMIC...
POLICY PAPERS
September 20, 2022
While all corners of the world have been touched by COVID-19, countries’ experiences with the virus have certainly not been universal. Staggering divergences in outcomes between countries—in terms of lives lost, economic carnage, secondary health losses, learning loss, and social trust and cohesion,...
BRIEFS
June 23, 2022
COVID-19 has shown the detrimental consequences of insufficient and fragmented financing for outbreak preparedness, prevention, and response (PPR). As the world seeks to recover from the current COVID-19 pandemic, and to mitigate recovery needs for future health crises, more must be done to accelera...
BRIEFS
May 11, 2022
As global health threats evolve, countries’ capacity to prepare for and respond to disease outbreaks is increasingly a global imperative. Now is the time to take concrete steps toward establishing sustained financing for pandemic PPR to help bring an end to the ongoing COVID-19 pandemic, combat futu...